Engrail Secures $157M Series B, Riding Wave of Neuropsychiatry Interest
TLDR: Engrail Therapeutics closed a $157M series B round to fund its neuropsychiatric pipeline. The success of the fundraising was partly due to interest from Big Pharma buyouts of neuropsychiatry-focused biotechs. Engrail